Menopause and Parkinson’s disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration
详细信息 查看全文
- 作者：Jose L. Labandeira-Garcia ; joseluis.labandeira@usc.es ; Ana I. Rodriguez-Perez ; Rita Valenzuela ; Maria A. Costa-Besada ; Maria J. Guerra
- 关键词：6-OHDA ; 6-hydroxydopamine ; ACE ; angiotensin converting enzyme ; ACEIs ; ACE inhibitors ; AII ; angiotensin II ; AT1 ; AII type 1 receptor ; AT2 ; AII type 2 receptor ; CNS ; central nervous system ; DA ; dopamine ; DPN ; 2 ; 3-Bis-4-hydroxyphenyl-propionitrile ; ER-β agonist ; E2 ; 17-β-estradiol ; ER-α ; estrogen receptor-α ; ER ; estrogen receptor ; ERT ; estrogen replacement therapy ; GPER1 ; GPR30 ; G protein-coupled estrogen receptor 1 ; HRT ; hormonal replacement therapy ; IL-1β ; interleukin-1β ; MPTP ; 1-methyl-4-phenyl-
- 刊名：Frontiers in Neuroendocrinology
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：43
- 期：Complete
- 页码：44-59
- 全文大小：2602 K
- 卷排序：43
文摘
Estradiol (E2) depletion increases nigral angiotensin system and inflammatory markers. Inhibition of nigral angiotensin mediates neuroprotection of E2 in Parkinson’s models. Astrocytes, neurons and microglia are involved in E2 regulation of nigral angiotensin. There is a critical period for the neuroprotective effects of E2 replacement therapy. Angiotensin receptor antagonists induce neuroprotection after the critical period.